menu
More than 40 large volume wearable injectors are presently available / under development for the administration of drugs, beyond insulin, including 15+ drug-device combinations
More than 40 large volume wearable injectors are presently available / under development for the administration of drugs, beyond insulin, including 15+ drug-device combinations
The convenience ofsubcutaneous route of drug administration and the reformulation of intravenousdrugs, reaching patent expiry

 

The convenience ofsubcutaneous route of drug administration and the reformulation of intravenousdrugs, reaching patent expiry, for SC delivery has provided an impetus to thedevelopment of large volume wearable injectors. In fact, according to theexperts in this field, the industry is putting in significant efforts todevelop efficient and effective drug-device combinations to deliver largevolumes of drugs over a convenient period of time.

 

To order this 540+page report, which features 175+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html

 

The USD 2.7 billion and USD 600 million (by 2030)financial opportunity within the large volume wearable injectors market for thedelivery of insulin  and of non-insulindrugs, respectively, has been analyzed across the following segments:

§  Typeof Device

  • Patch Pump / Injectors
  • Infusion Pump / Injectors

 

§  ProductUsability

  • Disposable
  • Re-usable

 

§  TherapeuticArea (for non-insulin drugs)

  • Neurological Disorders
  • Cardiovascular Disorders
  • Oncological Disorders
  • Infectious Disorders

 

§ Key geographical regions 

  • North America
  • Europe
  • Asia Pacific

 

The report Large Volume Wearable Injectors Market (5th Edition), 2020-2030:Focus on Bolus, Basal and Continuous Delivery Devices. features the following companies, which we identified tobe key players in this domain:

§ Becton Dickinson

§ Bespak (subsidiary of Consort Medical)

§ CeQur

§ Debiotech

§ Eli Lilly

§ Enable Injections

§ Insulet

§ Medtronic

§ PharmaSens

§ Roche

§ SOOIL Development

§ Sonceboz

§ Sensile Medical (acquired by Gerresheimer)

§ SteadyMed Therapeutics (acquired by United Therapeutics)

§ Tandem Diabetes Care

§ Weibel CDS (acquired by SHL Medical)

§ West Pharmaceutical Services

 

 

 

 

Table of Contents

 

1.Preface

2. Executive Summary


3. Introduction

4. LargeVolume Wearable Injectors: Current Market Landscape

5. ProductCompetitiveness Analysis 

6. LargeVolume Wearable Injectors: Key Players

7. DrugDevice Combinations: Tabulated Profiles

8. Partnershipsand Collaborations

9. KeyAcquisition Targets

10.Patent Analysis

11. LargeVolume Wearable Injectors: Likely Drug Candidates

 

12. EmergingTrends on Social Media

 

13.Clinical Trial Analysis

 

14. CaseStudy: Role of CMOs in Device Development and Manufacturing

 

15. Regulatoryand Reimbursement Landscape for Medical Devices

 

16.Market Sizing and Opportunity Analysis

 

17. SWOTAnalysis

 

18.Executive Insights

 

19.Appendix 1: Tabulated Data

 

20.Appendix 2: List of Companies and Organizations

 

To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com